Do Not Use Flovent on Top of Trelegy
You should not add Flovent (fluticasone propionate) to Trelegy (fluticasone furoate/umeclidinium/vilanterol) because this would result in dangerous duplication of inhaled corticosteroid therapy, significantly increasing your risk of systemic corticosteroid side effects without additional clinical benefit 1.
Why This Combination Is Problematic
Duplication of Corticosteroid Therapy
Trelegy already contains fluticasone furoate as its inhaled corticosteroid component (either 100 mcg or 200 mcg per dose) 1. Adding Flovent (fluticasone propionate) means you would be:
- Taking two different corticosteroids simultaneously - both fluticasone furoate (in Trelegy) and fluticasone propionate (Flovent)
- Dramatically increasing total corticosteroid exposure without medical justification
- Violating basic prescribing principles that warn against combining medications from the same drug class for the same indication
Serious Safety Risks
The combined corticosteroid burden creates multiple hazards:
Systemic corticosteroid effects 1:
- Hypercorticism and adrenal suppression
- Decreased bone mineral density and increased fracture risk
- Glaucoma and cataracts with long-term use
- Increased risk of pneumonia (especially in COPD patients)
- Growth suppression in children
- Immunosuppression with increased infection risk
No additional benefit: Research shows that fluticasone furoate and fluticasone propionate have similar efficacy profiles when used at appropriate doses 2, 3. Stacking them provides no therapeutic advantage.
What the Evidence Shows
Pharmacologic Differences Don't Justify Combination
While fluticasone furoate and fluticasone propionate are structurally different molecules with distinct pharmacokinetic properties 4, 5, this does not mean they should be used together:
- Fluticasone furoate has prolonged lung retention (mean absorption time ~7 hours vs 2.1 hours for propionate) and demonstrates absorption rate-limited pharmacokinetics 4
- Both drugs suppress the HPA axis in a dose-dependent manner 5
- Combining them would simply add their systemic effects together, multiplying risks
Prior Studies on Concurrent Corticosteroid Use
One study examined concurrent use of intranasal fluticasone propionate with inhaled fluticasone propionate and found no additional HPA-axis suppression 6. However, this is fundamentally different from your situation because:
- Intranasal corticosteroids have much lower systemic absorption than inhaled corticosteroids
- The study specifically looked at adding a different route (nasal) to inhaled therapy
- It does not support combining two inhaled corticosteroids
What You Should Do Instead
If Asthma Control Is Inadequate on Trelegy
Step up within Trelegy dosing 1:
- If currently on Trelegy 100/62.5/25 mcg, increase to Trelegy 200/62.5/25 mcg once daily
- This doubles your inhaled corticosteroid dose safely within a single product
Ensure proper inhaler technique:
- Verify you're using the Ellipta device correctly
- Rinse mouth after each use to reduce local side effects and systemic absorption 7
Optimize adherence:
- Trelegy is once-daily dosing; confirm you're taking it consistently at the same time each day
If COPD Symptoms Are Uncontrolled
Trelegy already provides maximal triple therapy (ICS/LAMA/LABA) 8. Adding more corticosteroid is not the answer. Instead:
- Reassess diagnosis and comorbidities
- Evaluate for exacerbating factors (infections, environmental exposures)
- Consider pulmonary rehabilitation
- Review rescue medication use patterns
Critical Pitfall to Avoid
Never assume "more is better" with corticosteroids. The dose-response curve for inhaled corticosteroids plateaus 3, meaning higher doses provide diminishing returns while side effects continue to increase linearly. The guideline-recommended approach is to use the minimum effective dose to maintain control 7.
If you're considering adding Flovent because Trelegy alone seems insufficient, this signals the need for a comprehensive reassessment of your respiratory condition, not medication stacking.